Inosine triphosphatase deficiency helps predict anaemia, anaemia management and response in chronic hepatitis C therapy
Paul J. Clark(QIMR Berghofer Medical Research Institute), Massimo Colombo(University of Milan), Andrew J. Muir(Duke University), E. Galmozzi(University of Milan), David M. Vock(Clinical Research Institute), Roberta D’Ambrosio(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Alessio Aghemo, Elisabetta Degasperi(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Maria Grazia Rumi(University of Milan), Alex Thompson(Clinical Research Institute), Thomas Urban(Duke University), Keyur Patel(Duke University)
Cited by 35
Related Papers
Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
|New England Journal of Medicine|2013|1.1k
A proposed system for the nomenclature of hepatitis C viral genotypes
|Hepatology|1994|1k
Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease
|Gastroenterology|2015|799
Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study
|The Lancet. Gastroenterology & hepatology|2022|664
Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response.
|Journal of Clinical Investigation|1996|661